A new assay was developed for the detection of hepatitis B virus (HBV) in human serum using amplification of a short viral DNA sequence by means of the polymerase chain reaction. As little as 0.4 fg viral DNA, corresponding to about 130 genome equivalents, per ml serum could be detected after the amplification procedure. This assay detected viral DNA in a number of patients with proven or suspected chronic HBV infection who were all negative for HBV DNA in the conventional hybridisation assay. We found HBV DNA in all of six HBeAg-positive and in three of eight HBeAg-negative HBsAg carriers, as well as in all of 11 patients with chronic liver disease with antibodies against the HBV core antigen (anti-HBc) as the sole marker for HBV infection, and in three of five apparently healthy individuals showing only anti HBc. Thus, this method is an important improvement for the diagnosis of persistent HBV infections, especially in patients where a definitive serological diagnosis is not possible.

KEY WORDS: DNA hybridisation, chronic HBV infection, diagnosis of persistent HBV infection

INTRODUCTION

Information about the presence or absence of hepatitis B virus (HBV) in the serum of an infected individual is desirable in several instances: for the assessment of disease activity in persistent infection, for monitoring therapeutic trials of antiviral agents, or for the evaluation of the infectivity of an individual's blood. The hepatitis B surface antigen (HBsAg) is the primary marker for the diagnosis of acute or chronic hepatitis B infection; however, although its presence is bound to the presence of viral genomic material in the liver, it correlates only roughly with viral replication and with the presence of infectious particles in the circulation. The hepatitis B e antigen (HBeAg) is a clearly better but also indirect marker for the presence of virus in the blood. By far the best diagnostic parameter in this respect is the viral DNA, which can be detected by a sensitive direct hybridisation assay [Bonino et al., 1981; Berninger et al., 1982]. The introduction of this test was one of the major improvements for the diagnosis of hepatitis B. It has not only led to a better understanding of the pathogenesis of the disease, especially of chronic HBV infection, but it is to date the most sensitive assay for the detection and assessment of the infectivity of an HBV-infected individual [Zyzik et al., 1986]. However, even this method has a detection limit of 10⁵–10⁶ virus particles per ml, which makes the exclusion of infectivity impossible; indeed, the infectivity of blood units determined negative for HBV DNA by the hybridisation assay could clearly be demonstrated [Krogsgaard et al., 1986]. Recently, a highly sensitive and specific method for the detection of DNA using enzymatic amplification of DNA sequences was introduced, which allows the detection of even a single copy of a gene [Saiki et al., 1985; Mullis and Faloona, 1987]. This test, known as polymerase chain reaction (PCR), was used initially to diagnose genetic abnormalities [Saiki et al., 1985; Verlaan-de Vries et al., 1986; Kogan et al., 1987], but has now also been adapted for the detection of viral pathogens, such as papilloma virus [Shibata et al., 1988], human immunodeficiency virus [Kwok et al., 1987; Loche and Mach, 1988; Laure et al., 1988], and hepatitis B virus [Larzul et al., 1988]. The use of the thermostable polymerase of the bacterium Thermus aquaticus (Taq) [Saiki et al., 1988] instead of the Klenow polymerase originally used [Saiki et al., 1985] greatly simplified this method and allowed its application for routine diagnostic procedures with large numbers of samples. Using this
technique, we developed a sensitive and highly specific test for the detection of HBV DNA in serum. In this paper we describe our initial findings with this new assay.

**PATIENTS, MATERIALS, AND METHODS**

Blood samples were obtained from chronic HBsAg carriers, patients with chronic liver disease of unknown etiology, healthy individuals previously infected with hepatitis B with antibodies against HBsAg (anti-HBs) and against the core antigen of HBV (anti-HBc), healthy persons with anti-HBc only, and healthy controls without any HBV marker.

HBV DNA was isolated from 250 μl serum by the method of Berninger et al. [1982] and dissolved in 20 μl 0.01 M Tris, 0.001 M EDTA, pH 7.4 (TE buffer).

Oligonucleotide primers were selected from conserved regions of the core gene of HBV according to the nucleotide sequence published by Ono et al. [1983]: primer I (5’): CTTGAGTTACTCTGTTTG (position 1937–1960); primer II (3’): TTAACATTGAGATTCCGAAGTTC (position 2434–2460). They were synthesized with a Biosearch 8700 DNA synthesizer (Biosearch, San Rafael, CA).

Amplification of HBV DNA was carried out by the polymerase chain reaction using a commercially available reagent kit (Gene Amp® DNA amplification kit, Perkin Elmer, Überlingen, FRG) according to the manufacturers’ instructions. Two microliters of purified DNA were used for each assay; concentration of the oligonucleotide primers was 0.5 μM. Prior to the addition of the Taq polymerase, samples were heated to 100°C for 10 min. Thereafter the mixture was cooled down to 37°C and 2.5 U of Taq polymerase in 0.5 μl were added. Incubation conditions were 37°C for 2 min (annealing), 70°C for 3 min (DNA synthesis), and 92°C for 1 min (denaturation). After ten such cycles the annealing temperature was increased to 50°C for another 30 cycles. After the amplification procedure 10 μl of sample were mixed with 1 μl gel loading buffer containing 50% sucrose, 0.05 M EDTA, 0.5 mg/ml xylene cyanol and 0.5 mg/ml bromophenol blue. Agarose gel electrophoresis was performed on 2% agarose gel according to standard procedures [Maniatis et al., 1982] and was subcloned into a pUC8 vector using standard methods [Maniatis et al., 1982]. The fragment was purified by agarose gel electrophoresis and used as template for the synthesis of labelled DNA by the method of “oligolabelling” [Feinberg and Vogelstein, 1983] with a “random primed DNA labelling kit” (Boehringer Mannheim, FRG) according to the manufacturer’s instructions.

For the direct detection of HBV DNA in serum without prior amplification the hybridisation assay described by Scotto et al. [1983] was used as modified by Zyzik et al. [1986]. HBV DNA was visualized using a RNA probe generated from total HBV DNA cloned into the plasmid pSP65. The radiolabelled probe was prepared with the SP6-Ribobsp® system as described by the manufacturer (Promega Biotech, Madison, WI). The detection limit of this test is about 0.3 pg of HBV DNA.

Tests for HBsAg, anti-HBs, anti-HBc, HBeAg, and antibodies against HBeAg (anti-HBe) were performed by radioimmunoassay using commercially available kits (Abbott Laboratories, North Chicago, IL).

**RESULTS**

The sensitivity of the new HBV DNA assay was evaluated by testing serial dilutions of a plasmid containing the entire HBV DNA (Fig. 1). After 30–40 cycles of the PCR, 0.01 fg of HBV DNA was clearly detected by Southern blot analysis. As little as 1 fg DNA was visible after amplification in the ethidium-bromide-stained agarose gel. Accordingly, the minimum detectable HBV DNA concentration in serum should be about 0.4 fg/ml, taking the concentration step during the DNA preparation and the amount of material used for the PCR (2 μl) into consideration.

The clinical significance of this assay could be demonstrated by the evaluation of a panel of sera which all had been found negative with the conventional DNA test (Table I). Six individuals who were HBsAg and HBeAg positive were found to be DNA positive after the amplification procedure, whereas of eight HBeAg-negative HBsAg carriers only three showed HBV DNA after the PCR. All of the carriers were asymptomatic. Analysis of sera of 11 patients with chronic liver disease who showed HBV DNA after the PCR. All of the carriers were asymptomatic. Analysis of sera of 11 patients with chronic liver disease who showed anti-HBc as the only marker of HBV infection revealed that all were DNA-positive (Fig. 2); on the other hand DNA was detectable only in three of five healthy individuals with anti-HBc only. Ten healthy persons infected previously with hepatitis B and ten individuals without any serological indication of an HBV infection served as controls; all were negative for HBV DNA. All these results were obtained by the Southern blot procedure; however, most of the positive sera were detectable already on the agarose gel electrophoresis.

**DISCUSSION**

We established a new assay for the detection of HBV in serum using the PCR for amplification of an HBV DNA sequence 524 base pairs long, which was then identified by agarose gel electrophoresis and Southern blotting. This test detects about 0.4 fg HBV DNA, or about 130 viral particles, per ml serum, showing a nearly 1,000-fold higher sensitivity than the direct hybridisation assay, which has a detection limit of about 0.3 pg HBV DNA, corresponding to 10⁵ genome equiv-
Fig. 1. Detection of HBV DNA in serial dilutions of a plasmid containing the entire HBV DNA; the amount of DNA which was amplified is indicated. The electrophoretic (left) and the Southern blot (right) analysis of the amplified 524 base pairs long DNA sequence is shown.

### TABLE I. Evaluation of Sera of Controls and Individuals With Different Forms of HBV Infection for HBV DNA by the PCR Amplification Procedure*

<table>
<thead>
<tr>
<th>Serological status</th>
<th>No. subjects</th>
<th>DNA after PCR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Positive</td>
</tr>
<tr>
<td>HBsAg+, HBeAg+, anti-HBe</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>HBsAg+, HBeAg+</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>HBsAg+, anti-HBe</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>Only anti-HBc, chronic liver disease</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Only anti-HBc, healthy</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Anti-HBs+, anti-HBc</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>No HBV marker</td>
<td>10</td>
<td>0</td>
</tr>
</tbody>
</table>

*All sera were negative for DNA with the conventional hybridisation assay.

alents per ml [Zyzik et al., 1986]. Thus, the sensitivity of our test is comparable to that of a similar assay described recently by Larzul et al. [1988]. The specificity of the test is guaranteed 1) by the use of Southern blotting showing the correct molecular weight of the amplified sequence, and 2) by using as probe a DNA sequence between the two primers which excludes the possibility of a false positive reaction due to hybridisation with primer sequences.

Sera of 40 individuals with markers of a previous HBV infection and sera of ten healthy controls without any markers of hepatitis B were analysed for the presence of HBV DNA by this assay. All sera were negative for HBV DNA in a conventional direct hybridisation test. After amplification the presence of HBV DNA could be demonstrated unequivocally in the majority of apparently healthy HBsAg carriers including all HBeAg-positive individuals, and in 11 patients with chronic liver disease with anti-HBc as the only marker of hepatitis B infection; in addition HBV DNA was found in three of five healthy individuals who were only anti-HBc positive.

These results show the high sensitivity of the new assay and demonstrate its usefulness for the diagnosis of different forms of HBV infection. Furthermore, our findings confirm and expand results of investigations using the conventional hybridisation assay for the detection of HBV DNA. These earlier studies showed that viral replication, as demonstrated by the presence of viral DNA in the circulation, is correlated with the presence of HBeAg and with symptomatic liver disease [Bonino et al., 1981; Berninger et al., 1982; Scotto et al., 1983; Zyzik et al., 1986]. Our data fit well into this pattern. All HBeAg-positive individuals tested were indeed also DNA positive, although they were apparently asymptomatic. These cases were selected for the amplification procedure because they were negative in the conventional hybridisation assay, which is positive in the vast majority of HBeAg-positive carriers; thus, this result could well mean that all HBeAg-positive HBsAg carriers are viremic. Even more important seems our finding that all patients with chronic liver disease showing anti-HBc as the only HBV marker were DNA positive, as well as three of five healthy individuals showing this serological profile. Using the direct hybridisation assay, Seelig et al. [1985] could detect HBV DNA in 9 of 50 patients with liver disease showing this pattern, whereas Brechot et al. [1985] were unable to demonstrate HBV DNA in the serum of 11 similar patients, although 9 of them had HBV DNA in their livers. Healthy individuals with anti-HBc only were found to be HBV DNA negative in the direct hybridisation assay by most authors [Scotto et al., 1983; Zyzik et al., 1986], nevertheless it is known from several studies that at least some of these individuals are...
Detection of HBV by Polymerase Chain Reaction

Fig. 2. Analysis of sera of 11 patients (1-11) with chronic liver disease and anti-HBc as the sole serological marker. 0 = negative control. a: Electrophoretic (left) and Southern blot (right) analysis of the amplified sequence; exposure time was 2 h. b: Same Southern blot as in panel a but exposed for 8 hr, showing clear positive signals for sera 8 and 11.

chronic carriers of HBV (the so-called low-level carriers) and are able to transmit the infection via blood transfusions [Hopkins et al., 1982; Sugg et al., 1982]. Such individuals can be well identified by the procedure described here. Thus, the detection of HBV DNA after amplification by PCR may become an indispensable method to clarify the extent of HBV infection in cases were a definitive serological diagnosis is not possible, e.g., where anti-HBc is the sole serological marker for hepatitis B infection.

REFERENCES


Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich GT (1988): Primer-directed enzymatic amplifi-